PETALUMA, Calif., Oct. 28 /PRNewswire/ -- Dr. David Osborne, Vice President of Product Development for Dow Pharmaceutical Sciences, presented “Principles of Drug Delivery and Skin Metabolism” to over 50 participants at the SID Basics of Skin: Pharmaceutics and Pharmacology Course in Philadelphia on October 15th, 2004. The Basics of Skin course was developed by dermatologists who work in both academia and industry and was presented for the benefit of professionals who work in dermatology research and development in both the public and private sectors.
(Logo: http://www.newscom.com/cgi-bin/prnh/20020221/SFTH055LOGO )
Dr. Osborne directs the Formulation Development Group and the Skin Biology and Drug Delivery laboratory at Dow Pharmaceutical Sciences, a Petaluma, California company that specializes in development of ethical topical drug products. His presentation covered: (a) the effect on drug delivery of various topical formulations including gels, creams, ointments and lotions, (b) basic drug transport processes and various routes whereby drugs penetrate the skin, (c) the effect of diseased skin on drug delivery and formulation selection, and (d) how skin metabolism can facilitate topical therapy using pro-drugs.
In his presentation, Dr. Osborne emphasized how formulation composition and excipients, the diseased skin, and metabolism within the skin have significant effects on the amount of drug that penetrates into and through the skin. These effects are measured quantitatively in Dow’s Skin Biology and Drug Delivery Laboratory, where both Franz static and Bronough flow-through cells are used to evaluate client formulations.
About Dow Pharmaceutical Sciences
Dow Pharmaceutical Sciences specializes in the development of dermatology and other topical products for pharmaceutical and biotechnology clients, including early stage consultation. They develop and optimize formulations with the help of their Skin Biology and Drug Delivery Laboratory. Dow also provides regulatory strategy development, non-clinical and clinical study design and management, and regulatory filings required to take dermatology products from inception through FDA approval.
For more information please visit http://www.dowpharmsci.com/
Photo: http://www.newscom.com/cgi-bin/prnh/20020221/SFTH055LOGOAP Archive: http://photoarchive.ap.org/PRN Photo Desk, photodesk@prnewswire.comDow Pharmaceutical Sciences
CONTACT: Steven R. Smith, Vice President, Marketing & BusinessDevelopment, of Dow Pharmaceutical Sciences, +1-707-665-4672 orssmith@dowpharmsci.com
Web site: http://www.dowpharmsci.com/